A rise in neutrophil-to-lymphocyte ratio of 3 or more after 2 months of therapy is associated with an increased risk for death in less than 1 year and treatment failure in less than 6 months, according to investigators.
Investigators of this retrospective observational cohort study evaluated outcomes with cabozantinib or other tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma (RCC) following immune checkpoint inhibition.
Patterns of disease spread varied significantly among patients with clear cell, papillary, and chromophobe renal cell carcinoma and may reflect differences in disease biology, according to investigators.
Patients who receive treatment with immune checkpoint inhibitors for advanced renal cell carcinoma and urothelial carcinoma are more likely to experience disease progression and death if they have liver metastases, a study found.
Sean McGowan, senior director of Biosimilars at AmerisourceBergen, and Brian Ansay, senior vice president of Sales and Corporate Services at ION Solutions, review 2020 biosimilar trends in oncology and forecast what is ahead in 2021.